Shares of Apogee Therapeutics (APGE) popped 18% in pre-market trading on Monday after the biotech firm said its lead drug, Zumilokibart, showed positive 52-week maintenance results in a Phase 2 trial for patients with moderate-to-severe Atopic Dermatitis, a type of skin condition.
The study found that patients maintained strong treatment responses with dosing every 3 or 6 months, suggesting the therapy could require less frequent dosing than current options.
Among patients who responded by Week 16, 75% on three-month dosing and 85% on six-month dosing maintained at least a 75% reduction in EASI scores. The drug also showed continued improvement in skin lesions and itch symptoms across the full study population. The therapy was generally well tolerated, with common side effects including conjunctivitis and upper respiratory infections, Apogee said.
“Consistent maintenance of response as well as deepening of responses over time were observed across key endpoints for both the 3- and 6-month dosing regimens, demonstrating a highly differentiated profile that could allow treatment to be administered as few as two times per year, compared with up to 26 injections annually for currently available therapies,” said Carl Dambkowski, Chief Medical Officer of Apogee
Get updates on this developing story on Stocktwits.
For updates and corrections, email newsroom[at]stocktwits[dot]com.